Liraglutide Cost in Colorado 2026: Cash Pay, Insurance, Medicaid and Compounded Options

What Does Liraglutide Cost in Colorado Without Insurance?

Without insurance, Coloradans pay an average of about $900 per month at retail pharmacies for brand-name liraglutide in 2026, though the Novo Nordisk list price sits at $1,349 per month. The gap between list price and actual cash-pay price reflects pharmacy-level discounts and GoodRx-type coupon programs that most pharmacies will accept at the counter.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist sold under two brand names: Victoza (1.2 mg or 1.8 mg, approved for type 2 diabetes) and Saxenda (3.0 mg, approved for chronic weight management). The FDA approved Victoza in 2010 and Saxenda in 2014; both remain brand-only in the U.S. market as of early 2026, meaning no FDA-approved generic tablet or injection is yet available. [1][2]

Price variation across Colorado is real. A 30-day supply at a Denver Walgreens may differ by $80 to $120 from the same supply at a Pueblo King Soopers pharmacy or a Colorado Springs independent compounding pharmacy. Calling ahead or running a GoodRx or NeedyMeds search using your specific ZIP code takes about three minutes and can surface meaningfully lower prices. [3]

The once-daily subcutaneous injection format also affects total cost: patients who miss doses do not recoup the cost of those wasted injections, so adherence directly shapes cost-effectiveness.

How Does Colorado Medicaid Cover Liraglutide?

Colorado Medicaid (Health First Colorado) covers liraglutide for type 2 diabetes management but does not cover it for chronic weight management as a standalone obesity indication. This means a member with a confirmed type 2 diabetes diagnosis who is prescribed Victoza (1.2 mg or 1.8 mg) may qualify for coverage, while a member prescribed Saxenda (3.0 mg) purely for weight loss will generally be denied. [4]

This distinction matters because both molecules are identical. The difference lies entirely in the approved indication and the dosage level. A prescriber writing for Saxenda under a weight-management diagnosis on a Medicaid member's chart will hit a coverage wall that does not exist for Victoza under a T2D diagnosis.

Health First Colorado does require prior authorization for Victoza. The PA criteria typically include:

• A confirmed type 2 diabetes diagnosis (ICD-10: E11.xx)
• A trial of metformin unless contraindicated
• HbA1c documentation within the past 90 days
• Prescriber attestation that the patient is not also using another GLP-1 agonist

Denials can be appealed. Colorado state law (C.R.S. 10-16-113) gives members the right to an expedited appeal within 72 hours for urgent situations and a standard appeal within 30 days for non-urgent denials. If the prescriber documents that the patient failed or cannot tolerate metformin, approval rates for the PA improve substantially.

Members near the federal poverty level who do not qualify for Medicaid but earn less than 250% FPL may qualify for Novo Nordisk's Patient Assistance Program, which provides free medication directly. [5]

Is Compounded Liraglutide Legal in Colorado?

Compounded liraglutide from a state-licensed 503A pharmacy is legal in Colorado, and it costs roughly $150 per month in 2026. That is an 83% reduction from the $900 average retail cash-pay price for the brand-name product.

The legal framework is federal, not state-specific. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug for an identified individual patient based on a valid prescription from a licensed practitioner. Liraglutide is not on the FDA's list of drugs that may not be compounded. A Colorado-licensed 503A pharmacy therefore may legally prepare liraglutide injections when a practitioner writes a patient-specific prescription. [6]

503B outsourcing facilities operate under different (and stricter) rules. They may compound without a patient-specific prescription but must register with the FDA, follow current Good Manufacturing Practice standards, and compound only drugs on FDA's shortage list or specific approved categories. Liraglutide's status on the shortage list has shifted; as of the date of this article, prescribers and patients should verify current FDA shortage-list status before assuming a 503B facility can legally supply it.

The HealthRX clinical team uses a three-question framework to assess whether compounded liraglutide is appropriate for a given Colorado patient:

1. Is the prescribing physician licensed in Colorado and the pharmacy a state-licensed 503A facility with a valid NABP accreditation?
2. Does the compounded formulation match the therapeutic dose range validated in the SCALE trials (0.6 mg to 3.0 mg titrated weekly)?
3. Has the patient been counseled that compounded liraglutide is not FDA-approved and that potency, sterility, and stability may differ from the brand product?

All three questions must be answered affirmatively before HealthRX clinicians will approve compounded liraglutide for a Colorado patient.

Coloradans should be cautious about online pharmacies offering "liraglutide" without requiring a prescription or without verifiable state licensure. The Colorado State Board of Pharmacy maintains a public license-verification database at dpo.colorado.gov. Checking a pharmacy's license before placing an order takes under two minutes and is the single most effective safety step a patient can take.

Which Insurance Plans Cover Liraglutide in Colorado?

Coverage varies widely across commercial insurers in Colorado. Most major carriers, including Anthem Blue Cross Blue Shield of Colorado, Cigna, Aetna, and Kaiser Permanente of Colorado, include liraglutide on their formularies but restrict it behind a prior authorization and, in many cases, a step-therapy requirement. [7]

Step therapy typically means the insurer requires the patient to try and fail (or document a contraindication to) a lower-cost diabetes medication before approving liraglutide. For type 2 diabetes, that usually means documented use of metformin and, in some plans, a sulfonylurea or SGLT-2 inhibitor. For weight management (Saxenda), step-therapy requirements are more variable and some plans exclude obesity drugs entirely.

Colorado's benchmark plan under the ACA marketplace (Connect for Health Colorado) does not mandate GLP-1 coverage for obesity across all metal tiers, though some gold and platinum plans have added it following employer-plan pressure since 2024.

A few practical steps that improve approval odds:

• Ask your prescriber to document your HbA1c, BMI, and prior medication history in the PA letter, not just the diagnosis code.
• Request that the PA letter cite the SCALE Obesity trial data showing 8.4 kg mean weight loss at 56 weeks with liraglutide 3.0 mg vs. 2.8 kg with placebo (P<0.001). [8]
• If denied, use Colorado's external review process. State law (C.R.S. 10-16-113.5) requires insurers to offer an independent external review for adverse benefit determinations.

Employer-sponsored self-funded plans in Colorado fall under ERISA and are not subject to Colorado's state insurance mandates, which means coverage rules for those plans can differ from fully-insured plans.

How the Novo Nordisk Savings Card Works in Colorado

Novo Nordisk offers two distinct savings programs, and they work differently depending on payer status. Commercially insured Colorado patients who are not on government programs (Medicaid, Medicare, CHIP, or any federally funded plan) may use the Novo Nordisk savings card for Victoza or Saxenda. The card can bring the patient's out-of-pocket cost to as low as $25 per month for Saxenda or $10 per month for Victoza, subject to eligibility rules and a monthly and annual cap. [9]

The income threshold for the manufacturer's patient assistance program (PAP), which provides free medication, is set at 400% of the federal poverty level for Saxenda and varies slightly for Victoza. A Colorado family of four earning under roughly $124 to 000 in 2026 may qualify.

Medicare Part D beneficiaries in Colorado cannot use manufacturer copay cards directly because federal anti-kickback rules prohibit them. However, the Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap, which took full effect in 2025, has meaningfully reduced exposure for Medicare patients who carry a GLP-1 prescription throughout the year.

"Patients who are uninsured or underinsured and who are not on government programs should always be offered the Novo Nordisk Patient Assistance Program before being advised to pay cash," states the American Association of Clinical Endocrinology's 2023 obesity management consensus statement. [10]

Clinical Evidence Behind the Cost: Is Liraglutide Worth the Price?

Understanding whether liraglutide justifies its cost requires looking at what the drug actually delivers. The SCALE Obesity trial (N=3,731 to 56 weeks) showed that liraglutide 3.0 mg produced a mean weight loss of 8.4 kg compared with 2.8 kg in the placebo group (P<0.001), with 63.2% of liraglutide patients achieving at least 5% weight loss vs. 27.1% on placebo. [8]

For type 2 diabetes, the LEADER trial (N=9,340, median 3.8 years) found that liraglutide 1.8 mg reduced major adverse cardiovascular events by 13% compared with placebo (hazard ratio 0.87; 95% CI 0.78 to 0.97; P<0.001 for non-inferiority, P=0.01 for superiority). [11] That cardiovascular benefit is clinically meaningful and contributes to value-based insurance coverage arguments.

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes designate liraglutide as a preferred agent for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, independent of baseline HbA1c. [12] That guideline language gives prescribers strong documented grounds for PA appeals when insurers attempt to restrict liraglutide to second-line use only.

Semaglutide (Ozempic, Wegovy) produces greater mean weight loss in head-to-head comparisons, roughly 14.9% at 68 weeks in STEP-1 (N=1,961) vs. liraglutide's 8.0% at 56 weeks in SCALE Obesity. [13] Patients and clinicians in Colorado choosing between agents should factor in that efficacy difference alongside the cost difference. At $900/month cash-pay for liraglutide vs. comparable cash pricing for semaglutide, liraglutide's lower cost may not fully offset a meaningful efficacy gap for patients whose primary goal is significant weight reduction.

How to Get Liraglutide via Telehealth in Colorado

Colorado law permits telehealth prescribing of liraglutide for both type 2 diabetes and chronic weight management. The Colorado Medical Practice Act does not require an in-person visit before a physician may prescribe a non-controlled substance, and liraglutide is not a controlled substance. [14]

A telehealth visit with a Colorado-licensed prescriber is therefore a legal and practical starting point. The visit typically takes 20 to 40 minutes and should include a review of:

• Current HbA1c or fasting glucose (for T2D indication)
• BMI and weight history (for obesity indication)
• Cardiovascular history and current medications
• History of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (contraindications to liraglutide)
• Pancreatitis history

After the visit, the prescriber sends an electronic prescription to any Colorado-licensed pharmacy, including mail-order pharmacies operating in the state. Compounded liraglutide via a 503A pharmacy also requires a patient-specific telehealth prescription, which many Colorado 503A pharmacies are set up to receive directly.

HealthRX clinicians prescribing liraglutide via telehealth in Colorado follow the Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy, which recommends initiating liraglutide at 0.6 mg once daily and increasing by 0.6 mg weekly to a target of 3.0 mg for weight management, or 1.2 mg to 1.8 mg for glycemic control. [15]

Strategies to Lower Your Liraglutide Cost in Colorado

Several concrete approaches can reduce what a Colorado patient actually pays out of pocket. Each carries different eligibility requirements.

GoodRx and coupon aggregators. GoodRx, RxSaver, and NeedyMeds regularly show Colorado retail prices of $750 to $870 per month for Saxenda, below the $900 average cash-pay rate. These coupons cannot be combined with insurance and cannot be used by federal program beneficiaries. [3]

Novo Nordisk savings card. Commercially insured patients not on government programs pay as low as $25 per month (Saxenda) or $10 per month (Victoza). Enrollment at NovoNordiskHCP.com or via in-office enrollment takes five minutes. [9]

Patient Assistance Program. Uninsured or underinsured Colorado patients below 400% FPL may receive free medication through the Novo Nordisk PAP. Applications require income verification and a prescriber signature.

503A compounded liraglutide. At approximately $150 per month from a Colorado-licensed 503A pharmacy, this option costs 83% less than average retail brand-name pricing. The trade-off is that compounded liraglutide is not FDA-approved for any indication, and patients bear responsibility for confirming pharmacy licensure.

Split-dose titration from Victoza. Some prescribers in Colorado have used Victoza (the diabetes-labeled product) at lower doses for weight management patients, which can result in lower acquisition costs in certain pharmacy and insurance contexts. This is an off-label approach and requires explicit shared decision-making documentation.

Specialty pharmacy networks. Some Colorado employers contract with specialty pharmacies (AllianceRx Walgreens, CVS Specialty, Optum Rx) that negotiate lower unit costs for GLP-1 agents. If your employer plan uses one of these networks, filling at a retail pharmacy instead of the designated specialty pharmacy may cost significantly more.

Liraglutide vs. Other GLP-1 Options in Colorado: A Cost Comparison

Colorado patients often weigh liraglutide against semaglutide (Ozempic for T2D, Wegovy for obesity) and tirzepatide (Mounjaro for T2D, Zepbound for obesity). A brief comparison on cost and efficacy helps frame the decision.

Semaglutide 2.4 mg (Wegovy) carries a list price of approximately $1,349 per month, similar to liraglutide's list price, but the STEP-1 trial (N=1,961) demonstrated 14.9% mean weight loss at 68 weeks, roughly double the liraglutide SCALE result. [13] For cash-pay Colorado patients, the cost-per-kilogram-lost ratio may actually favor semaglutide.

Tirzepatide (Zepbound, 15 mg) produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539), with a list price near $1,060 per month after a recent Eli Lilly price reduction. [16] Colorado Medicaid does not yet cover tirzepatide for weight management either.

Compounded semaglutide was widely available in Colorado through 2024 and early 2025, but FDA shortage-list removal of semaglutide has complicated compounding legality. Compounded liraglutide, which has not faced the same shortage-list volatility, may be a more legally stable compounding option in Colorado through 2026.

The right choice depends on a patient's insurance status, metabolic goals, cardiovascular risk, and tolerance for injection frequency. Liraglutide's once-daily dosing is a disadvantage vs. semaglutide's once-weekly schedule for many patients, and that adherence factor has real cost implications when missed doses represent wasted drug.